LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Search

Charles River Laboratories International Inc

Închisă

SectorSănătate

168.66 -1.6

Rezumat

Modificarea prețului

24h

Curent

Minim

167.72

Maxim

174.52

Indicatori cheie

By Trading Economics

Venit

2.9M

56M

Vânzări

-27M

1B

P/E

Medie Sector

592.3

105.69

EPS

2.43

Marjă de profit

5.529

Angajați

18,700

EBITDA

-23M

198M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+11.95% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-487M

8.3B

Deschiderea anterioară

170.26

Închiderea anterioară

168.66

Sentimentul știrilor

By Acuity

21%

79%

49 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

Charles River Laboratories International Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 nov. 2025, 21:34 UTC

Câștiguri

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 nov. 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 nov. 2025, 23:42 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 nov. 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 nov. 2025, 23:24 UTC

Câștiguri

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 nov. 2025, 23:24 UTC

Câștiguri

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 nov. 2025, 23:23 UTC

Câștiguri

JBS NV 3Q EPS 52c >JBS

13 nov. 2025, 23:23 UTC

Câștiguri

JBS NV 3Q Sales $22.6B >JBS

13 nov. 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 nov. 2025, 22:02 UTC

Câștiguri

Nu Holdings 3Q Net $783M >NU

13 nov. 2025, 22:01 UTC

Câștiguri

Nu Holdings 3Q Rev $4.2B >NU

13 nov. 2025, 21:51 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 nov. 2025, 21:50 UTC

Câștiguri

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 nov. 2025, 21:45 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 nov. 2025, 21:41 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 nov. 2025, 21:36 UTC

Achiziții, Fuziuni, Preluări

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 nov. 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 nov. 2025, 21:33 UTC

Câștiguri

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 nov. 2025, 21:31 UTC

Câștiguri

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 nov. 2025, 21:25 UTC

Câștiguri

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 nov. 2025, 21:25 UTC

Câștiguri

Figure Tech Solutions 3Q EPS 34c >FIGR

13 nov. 2025, 21:23 UTC

Câștiguri

Intchains Group 3Q Rev $1.3M >ICG

13 nov. 2025, 21:03 UTC

Câștiguri

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 nov. 2025, 21:02 UTC

Câștiguri

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 nov. 2025, 21:01 UTC

Câștiguri

Applied Materials 4Q Rev $6.8B >AMAT

13 nov. 2025, 21:01 UTC

Câștiguri

Applied Materials 4Q Gross Margin 48.0% >AMAT

Comparație

Modificare preț

Charles River Laboratories International Inc Așteptări

Obiectiv de preț

By TipRanks

11.95% sus

Prognoză pe 12 luni

Medie 192 USD  11.95%

Maxim 225 USD

Minim 165 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCharles River Laboratories International Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

12 ratings

6

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

117.16 / 144.77Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

49 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat